The Covid-19 pandemic is expected to further affect RhoVac's clinical phase IIb study
LUND, Sweden, Oct. 12, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 ("BRaVac"), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitment rate in September now indicates full recruitment in Q2 2021. To reduce the effect of the delays caused by the pandemic, the number of clinics will be increased. The study is still expected to be carried out with existing funding.
BRaVac is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating whether treatment with the drug candidate RV001 can prevent or limit recurrence and development of cancer, measured as a slower development of PSA (Prostate Specific Antigen) in prostate cancer patients compared to the control group. Based on the current recruitment rate, full recruitment in the study is forecast to take place Q2 2021. To limit the impact of the pandemic as much as possible, Rhovac will further increase the number of clinics included in the study to a total of approx. 40 clinics. The new clinics will open primarily in the United States. Regardless of the delays, the study is still expected to be carried out within the framework of existing funding.
RhoVac CEO, Anders Månsson, comments: "Like all other companies, RhoVac is affected by the pandemic and its countermeasures. We are now focusing on minimising delays as far as possible by adding new clinics, something we can do thanks to our financial strength. We know that RV001 is a very valuable asset. We will now complete the study as soon as possible and continue our work to secure a deal with a partner who will eventually take our drug candidate to market and make it available to patients."
This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-10-2020 08:30 CET.
For further information, please contact:
Anders Månsson - CEO
Phone number: +46-73-751-72-78
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Company Codes: ISIN:SE0007784319